Entering text into the input field will update the search result below

Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy

Apr. 04, 2022 1:10 PM ETAgile Therapeutics, Inc. (AGRX)22 Comments


  • Agile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics.
  • Slow uptake is forcing me to adjust my investment strategy to avoid locking up my capital while the company is burning through cash and the growth trajectory is uncertain.
  • I review the company's Q4 and full-year 2021 earnings. The numbers were underwhelming but positive trends are budding.
  • I have been waiting for a strong capitulation event. The recent sell-off could be that event. I discuss my new AGRX strategy.
  • Looking for more investing ideas like this one? Get them exclusively at Compounding Healthcare. Learn More »
Businessman trading online stock market on teblet screen, digital investment concept

nespix/iStock via Getty Images

Agile Therapeutics (NASDAQ:AGRX) just completed its first full year as a commercial company, which was highlighted by an attractive growth curve for its flagship product, Twirla. Agile has been working hard to establish Twirla in the contraceptive market despite crushing

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare, and sign up for a free trial.  

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AGRX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.